Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Adine Edwards

Nurse Practitioner, Primary Care Springfield, OH Nurse Practitioner

NPI 1538702162 CMS profile 10893344

100 Medical Center Dr, Springfield, OH 45504

Open in the dashboard

General payments

$14,020

776 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adine Edwards of Springfield, OH is reported in the CMS Open Payments database as having received $14,020 across 776 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,578 172
2024 General $3,316 172
2023 General $2,699 172
2022 General $2,294 143
2021 General $2,132 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adine Edwards
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Adine Edwards were reported at $3,578. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Adine Edwards Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,132 $137 $39–$445 $132
2022 $2,294 $139 $44–$421 $149
2023 $2,699 $163 $53–$481 $160
2024 $3,316 $176 $54–$511 $164
2025 $3,578 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,760 222 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,643 111 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,539 89 payments
  4. Janssen Biotech, Inc. $1,279 71 payments
  5. QOL Medical, LLC $681 31 payments
  6. Gilead Sciences, Inc. $602 32 payments
  7. E.R. Squibb & Sons, L.L.C. $533 5 payments
  8. Celgene Corporation $417 28 payments
  9. Ardelyx, Inc. $308 15 payments
  10. Ipsen Biopharmaceuticals, Inc $282 12 payments
  11. Other $2,977 160 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,851 773 payments
  2. Education $169 3 payments
Products named General payments · program years 2021–2025
  1. ENTYVIO $1,327 77 payments
  2. CREON $1,254 66 payments
  3. XIFAXAN $1,254 78 payments
  4. LINZESS $1,238 67 payments
  5. STELARA $1,062 65 payments
  6. RINVOQ $994 62 payments
  7. ZEPOSIA $812 31 payments
  8. SIMPONI ARIA $677 42 payments
  9. SIMPONI $677 42 payments
  10. TREMFYA $668 23 payments
  11. Other $7,675 444 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

484

Median for Nurse Practitioner: 389

Drug cost

$144,995

Median for Nurse Practitioner: $21,885

Branded share of claims

19.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 41 $119,289
Linzess Linaclotide Brand 16 $14,308
Dexlansoprazole Dr Dexlansoprazole Brand 11 $2,357
Pantoprazole Sodium Generic 162 $2,249
Ondansetron Odt Ondansetron Brand 27 $2,166
Sucralfate Generic 47 $1,327
Colestipol Hcl Generic 25 $1,239
Omeprazole Generic 52 $1,031
Dicyclomine Hcl Generic 37 $488
Famotidine Generic 31 $358

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$17,038

Medicare's payments for the services billed

Medicare patients

177

Average age 72

Services billed

287

99 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 36%
Ischemic heart disease 35%
Depression 35%
COPD 28%
Atrial fibrillation 26%
Chronic kidney disease 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $358
$358 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $325
$325 41 —
STELARA
  • Janssen Biotech, Inc. $271
$271 — —
LINZESS
  • AbbVie, Inc. $188
  • Ironwood Pharmaceuticals, Inc $63
$251 16 —
RINVOQ
  • AbbVie, Inc. $217
$217 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

776 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record